Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableEnded earlyNCT03738553
What this trial is testing

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

Who this might be right for
HER2-positive Breast Cancer
University of Washington 13
Testing effectiveness (Phase 2)Study completedNCT00136539
What this trial is testing

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

Who this might be right for
Breast Cancer
Harold J. Burstein, MD, PhD 41
Testing effectiveness (Phase 2)Looking for participantsNCT07335081
What this trial is testing

CtDNA in HER2+ EBC Neoadjuvant Treatment

Who this might be right for
Breast Cancer
Shanghai Jiao Tong University School of Medicine 60
Testing effectiveness (Phase 2)Ended earlyNCT02154529
What this trial is testing

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Who this might be right for
HER-2 Positive Breast CancerMetastatic Malignant Neoplasm to Brain
Kadmon Corporation, LLC 17
Testing effectiveness (Phase 2)Looking for participantsNCT07492394
What this trial is testing

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Hebei Medical University Fourth Hospital 60
Not applicableStudy completedNCT04498481
What this trial is testing

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Who this might be right for
Breast Cancer
Pfizer 1
Large-scale testing (Phase 3)Looking for participantsNCT07615751
What this trial is testing

Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 502
Not applicableStudy completedNCT03841266
What this trial is testing

Recurrence Risk Evaluation by 21-gene Detection

Who this might be right for
Relationship and Consistency Analysis
Xijing Hospital 220
Not applicableUnknownNCT05750693
What this trial is testing

PIK3CA in HER2+ BC and pCR Trial

Who this might be right for
HER2-positive Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 58
Large-scale testing (Phase 3)UnknownNCT02344472
What this trial is testing

Detect V / CHEVENDO (Chemo vs. Endo)

Who this might be right for
Metastatic Breast Cancer
Prof. Wolfgang Janni 271
Not applicableUnknownNCT05491057
What this trial is testing

Treatment Patterns of Neratinib in HER2+ EBC in China

Who this might be right for
Breast Cancer
Pierre Fabre Medicament 500
Large-scale testing (Phase 3)Study completedNCT00004067
What this trial is testing

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Who this might be right for
Breast Cancer
NSABP Foundation Inc 2,130
Testing effectiveness (Phase 2)Study completedNCT02488564
What this trial is testing

Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer

Who this might be right for
HER-2 Positive Breast Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 49
Not applicableUnknownNCT05167643
What this trial is testing

H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study

Who this might be right for
Advanced HR+ HER2 Negative Breast Carcinoma
Tianjin Medical University Cancer Institute and Hospital 40
Not applicableUnknownNCT02656589
What this trial is testing

MicroRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin

Who this might be right for
Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Large-scale testing (Phase 3)Ended earlyNCT03199885
What this trial is testing

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast AdenocarcinomaMetastatic HER2-Positive Breast CarcinomaRecurrent Breast Adenocarcinoma+5 more
National Cancer Institute (NCI) 190
Testing effectiveness (Phase 2)Study completedNCT02403271
What this trial is testing

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerBreast CancerPancreatic Cancer
Pharmacyclics LLC. 124
Large-scale testing (Phase 3)Looking for participantsNCT07294508
What this trial is testing

Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2 + Breast Cancer
Shanghai Henlius Biotech 706
Testing effectiveness (Phase 2)Looking for participantsNCT07299825
What this trial is testing

A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Who this might be right for
Her 2 Positive Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 40
Next Page